12例原发性骨髓纤维化合并肝硬化患者的临床特征分析

王宣; 何婷婷; 张宁; 周超; 王葽; 白云峰; 张晶晶; 付双楠; 梁肖肖; 李昕; 宫嫚

doi:10.3969/j.issn.1001-5256.2020.11.025

12例原发性骨髓纤维化合并肝硬化患者的临床特征分析

DOI: 10.3969/j.issn.1001-5256.2020.11.025

解放军总医院第五医学中心中西医结合科

基金项目:

国家科技重大专项（2018ZX10725506-002）；

详细信息

中图分类号: R575.2;R551.3
计量
- 文章访问数: 571
- HTML全文浏览量: 18
- PDF下载量: 101
- 被引次数: 0
出版历程
- 出版日期: 2020-11-20

Clinical characteristics of 12 patients with primary myelofibrosis and liver cirrhosis

Department of Integrative Medicine,The Fifth Medical Center of Chinese PLA General Hospital

Research funding:

摘要

摘要:
<正>原发性骨髓纤维化（primary myelofibrosis,PMF）是由异常造血干细胞的克隆性增殖,导致进行性骨髓纤维化的一种骨髓增殖性肿瘤[1]。有研究[2]发现部分骨髓纤维化患者可出现肝脏硬度值升高。近年来,亦有研究者对PMF合并肝硬化、门静脉高压、消化道出血等进行过临床报道[3-4],但病例数较少。此外,PMF作为一种罕见病,常伴有脾大、门静脉高压、进行性血细胞减少及消化道出血等,与肝硬化表现较为相似,当该病合并肝硬化时,易出现漏诊、误诊。PMF可导致肝硬化,但其进展至肝硬化的间隔时间不详,且无相关临床报道。因此,通过对本院PMF合并肝硬化病例的总结,并结合文献复习,有助于更好地认识PMF与肝硬化之间的关系,对临床早期诊断,减少漏诊、误诊十分重要。
- 原发性骨髓纤维化 /
- 肝硬化 /
- 脾大 /
- 体征和症状
- primary myelofibrosis /
- liver cirrhosis /
- splenomegaly /
- signs and symptoms

HTML全文

参考文献(15)

[1] TEFFERI A. Pathogenesis of myelofibrosis with myeloid metaplasia[J]. J Clin Oncol,2005,23(33):8520-8530.

[2] WEBB M,SHIBOLET O,HALPERN Z,et al. Assessment of liver and spleen stiffness in patients with myelofibrosis using FibroScan and Shear wave elastography[J]. Ultrasound Q,2015,31(3):166-169.

[3] ZHANG L,FU XX,LI X. One case of myelofibrosis with cirrhotic portal hypertension[J]. J Clin Hepatol,2015,31(2):280-281.(in Chinese)张莉，付晓霞，李洵．骨髓纤维化合并肝硬化门静脉高压1例报告[J]．临床肝胆病杂志，2015,31(2):280-281.

[4] LIU WH,LI H,LIANG YP,et al. A case of primary myelofibrosis with esophageal variceal bleeding[J]. Chin J Gerontol,2014,34(2):532-533.(in Chinese)刘维花，李慧，梁玉萍，等．原发性骨髓纤维化合并食管静脉曲张破裂出血1例[J]．中国老年学杂志，2014,34(2):532-533.

[5] ARBER DA,ORAZI A,HASSERJIAN R,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016,127(20):2391-2405.

[6] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.

[7] WAN XH,LU XF. Diagnostics[M]. Beijing:People’s Medical Publishing House,2013:183.(in Chinese)万学红，卢雪峰．诊断学[M]．北京:人民卫生出版社，2013:183.

[8] CHEN HZ,LIN GW. Practice of internal medicine[M]. Beijing:People’s Medical Publishing House,2009:2419.(in Chinese)陈灏珠，林果为．实用内科学[M]．北京:人民卫生出版社，2009:2419.

[9] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J]. J Prac Hepatol,2018,21(1):21-31.(in Chinese)中华医学会肝病学分会．肝硬化腹水及相关并发症的诊疗指南[J]．实用肝脏病杂志，2018,21(1):21-31.

[10] HU J,ZHANG FK. The pathomechanism of bone marrow fibrosis[J]. J Clin Hematol,2019,32(4):555-558.(in Chinese)胡靖，张凤奎．骨髓间质纤维化发生的病理机制认识[J]．临床血液学杂志，2019,32(4):555-558.

[11] KUTER DJ,BAIN B,MUFTI G,et al. Bone marrow fibrosis:Pathophysiology and clinical significance of increased bone marrow stromal fibres[J]. Br J Haematol,2007,139(3):351-362.

[12] CERVANTES F,DUPRIEZ B,PEREIRA A,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment[J]. Blood,2009,113(13):2895-2901.

[13] TEFFERI A,MUDIREDDY M,MANNELLI F,et al. Blast phase myeloproliferative neoplasm:Mayo-AGIMM study of 410 patients from two separate cohorts[J]. Leukemia,2018,32(5):1200-1210.

[14] ZHONG JP. A case of liver cirrhosis with chronic primary myelofibrosis[J]. J Clin Hepatol,1997,13(3):49-50.(in Chinese)钟建平．肝硬化合并慢性原发性骨髓纤维化一例[J]．临床肝胆病杂志，1997,13(3):49-50.

[15] DESTERKE C,MARTINAUD C,RUZEHAJI N,et al. Inflammation as a keystone of bone marrow stroma alterations in primary myelofibrosis[J]. Mediators Inflamm,2015,2015:415024.

施引文献

资源附件(0)

访问统计